País: Singapur
Idioma: anglès
Font: HSA (Health Sciences Authority)
MONTELUKAST SODIUM 10.4 MG EQV MONTELUKAST (Core Tablet)
ORGANON SINGAPORE PTE. LTD.
R03DC03
10 mg
TABLET
MONTELUKAST SODIUM 10.4 MG EQV MONTELUKAST (Core Tablet) 10 mg
ORAL
Prescription Only
Organon Pharma (UK) Limited
ACTIVE
1998-05-16
SG-MK0476-MF-042014 PRODUCT CIRCULAR Tablets/Chewable Tablets/Oral Granules SINGULAIR® (montelukast sodium, MSD) I. THERAPEUTIC CLASS SINGULAIR (montelukast sodium) is a selective and orally active leukotriene receptor antagonist that specifically inhibits the cysteinyl leukotriene CysLT 1 receptor. II. INDICATIONS SINGULAIR is indicated in adult and pediatric patients 1 year of age and older for the prophylaxis and chronic treatment of asthma, including the prevention of day- and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction. SINGULAIR is indicated for the relief of daytime and nighttime symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older, and perennial allergic rhinitis in adults and pediatric patients 1 year of age and older). III. DOSAGE AND ADMINISTRATION SINGULAIR should be taken once daily. For asthma, the dose should be taken in the evening. For allergic rhinitis, the time of administration may be individualized to suit patient needs. Patients with both asthma and allergic rhinitis should take only one tablet daily in the evening. Adults 15 Years of Age and Older with Asthma and/or Allergic rhinitis The dosage for adults 15 years of age and older is one 10-mg tablet daily. Pediatric Patients 6 to 14 Years of Age with Asthma and/or Allergic rhinitis The dosage for pediatric patients 6 to 14 years of age is one 5-mg chewable tablet daily. Pediatric Patients 2 to 5 Years of Age with Asthma and/or Allergic rhinitis The dosage for pediatric patients 2 to 5 years of age is one 4-mg chewable ta Llegiu el document complet
SG-MK0476-MF-052019 PRODUCT CIRCULAR Tablets/Chewable Tablets/Oral Granules SINGULAIR® (montelukast sodium) I. THERAPEUTIC CLASS SINGULAIR (montelukast sodium) is a selective and orally active leukotriene receptor antagonist that specifically inhibits the cysteinyl leukotriene CysLT 1 receptor. II. INDICATIONS SINGULAIR is indicated in adult and pediatric patients 1 year of age and older for the prophylaxis and chronic treatment of asthma, including the prevention of day- and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction. SINGULAIR is indicated for the relief of daytime and nighttime symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older, and perennial allergic rhinitis in adults and pediatric patients 1 year of age and older). Because the benefits of SINGULAIR may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis, reserve use for patients who have an inadequate response or intolerance to alternative therapies. III. DOSAGE AND ADMINISTRATION SINGULAIR should be taken once daily. For asthma, the dose should be taken in the evening. For allergic rhinitis, the time of administration may be individualized to suit patient needs. Patients with both asthma and allergic rhinitis should take only one tablet daily in the evening. Adults 15 Years of Age and Older with Asthma and/or Allergic rhinitis The dosage for adults 15 years of age and older is one 10-mg tablet daily. Pediatric Patients 6 to 14 Years of Age with Asthma and/or Allergic rhinitis The dosage for pediatric patients 6 to 14 years of age is one 5-mg chewable tablet daily. Pediatric Patients 2 to 5 Years of Age with Asthma and/or Allergic rhinitis The dosage for pediatric patients 2 to 5 years of age is one 4-mg chewable tablet daily or one packet of 4-mg oral granules daily. Pediatric Patients 1 to 2 Years of Age with Asthma The dosage for pediatric patients 1 to 2 years of ag Llegiu el document complet